Cardiology biotech Kardigan filed for a Nasdaq IPO under ticker {$KARD}, joining a growing roster of clinical-stage drug developers tapping reopened capital markets.
May 26, 2026 08:15 PM EDT
IPOs
Kardigan readies Nasdaq IPO to back three cardio drugs
Kyle LaHucik
Biotech Correspondent
Kardigan targets IPO to support cardiology pipeline progression - Pharmaceutical Technology
Cardio drugmaker Kardigan plans to go public
Listings (IPO) | KrASIA
Make IPOs great again
As SpaceX and OpenAI Prepare for Public Debuts, What Recent IPO History Signals
Wall Street May Not Be Ready For What Happens If SpaceX, OpenAI And Anthropic Hit Public Markets Under Na
Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical…
Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of…
Odyssey Therapeutics raised $279 million in an upsized IPO priced at $18 a share, with the autoimmune disease biotech set to…
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.
Kordata, a BIOS Ltd spinout, will advance next-generation clinical trial sites powered with neural recording technologies and…
Kordata launched from stealth, spun out of BIOS to target CNS trials with neurotech and enterprise
